Candel Therapeutics, Inc. (CADL)
Largest Insider Buys in Sector
CADL Stock Price History Chart
CADL Stock Performance
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Insider Activity of Candel Therapeutics, Inc.
Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $0 and sold $0 worth of Candel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $7.43M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,950 shares for transaction amount of $45,984 was made by Martell Christopher (director) on 2022‑12‑09.
List of Insider Buy and Sell Transactions, Candel Therapeutics, Inc.
| 2022-12-09 | Martell Christopher | director | 23,950 0.0761% | $1.92 | $45,984 | -35.41% | ||
| 2022-12-09 | Tak Paul Peter | Chief Executive Officer | 12,935 0.0411% | $1.92 | $24,835 | -35.41% | ||
| 2022-12-09 | PAPA JOSEPH C | director | 35,018 0.1125% | $1.94 | $67,935 | -35.41% | ||
| 2022-12-09 | Tyagarajan Seshu | Chief Technology Officer | 10,358 0.0331% | $1.93 | $19,991 | -35.41% | ||
| 2022-12-09 | Amello Jason | Chief Financial Officer | 2,468 0.0079% | $1.93 | $4,763 | -35.41% | ||
| 2022-12-08 | Martell Christopher | director | 3,050 0.0093% | $1.68 | $5,124 | -28.68% | ||
| 2022-12-08 | Tak Paul Peter | Chief Executive Officer | 3,050 0.0094% | $1.70 | $5,185 | -28.68% | ||
| 2022-12-08 | Amello Jason | Chief Financial Officer | 3,100 0.0095% | $1.69 | $5,239 | -28.68% | ||
| 2022-12-08 | PAPA JOSEPH C | director | 3,014 0.0093% | $1.70 | $5,124 | -28.68% | ||
| 2022-12-08 | Tyagarajan Seshu | Chief Technology Officer | 3,000 0.0092% | $1.69 | $5,070 | -28.68% | ||
| 2022-12-08 | Barone Francesca | Chief Scientific Officer | 1,238 0.0036% | $1.61 | $1,993 | -28.68% | ||
| 2021-07-29 | Manning Paul B | 1.63M 7.6346% | $8.00 | $13M | -24.18% | |||
| 2021-07-29 | Martell Christopher | director | 125,000 0.5873% | $8.00 | $1M | -24.18% | ||
| 2021-07-29 | Tak Paul Peter | Chief Executive Officer | 25,000 0.1175% | $8.00 | $200,000 | -24.18% | ||
| 2021-07-29 | Canepa John J | Chief Financial Officer | 10,125 0.0476% | $8.00 | $81,000 | -24.18% | ||
| 2021-07-29 | Nguyen Diem | director | 10,000 0.047% | $8.00 | $80,000 | -24.18% | ||
| 2021-07-29 | Caffo Nathan | Chief Business Officer | 6,000 0.0282% | $8.00 | $48,000 | -24.18% | ||
| 2021-07-27 | Manning Paul B | director | 36,000 0.1622% | $7.36 | $264,834 | -18.36% |
Insider Historical Profitability
| Manning Paul B | 1681000 5.8126% | $5.71 | 2 | 0 | <0.0001% | |
| Martell Christopher | director | 152000 0.5256% | $5.71 | 3 | 0 | <0.0001% |
| Tak Paul Peter | Chief Executive Officer | 40985 0.1417% | $5.71 | 3 | 0 | <0.0001% |
| PAPA JOSEPH C | director | 38032 0.1315% | $5.71 | 2 | 0 | <0.0001% |
| Tyagarajan Seshu | Chief Technology Officer | 13358 0.0462% | $5.71 | 2 | 0 | <0.0001% |
| Canepa John J | Chief Financial Officer | 10125 0.035% | $5.71 | 1 | 0 | <0.0001% |
| Nguyen Diem | director | 10000 0.0346% | $5.71 | 1 | 0 | <0.0001% |
| Caffo Nathan | Chief Business Officer | 6000 0.0207% | $5.71 | 1 | 0 | <0.0001% |
| Amello Jason | Chief Financial Officer | 5568 0.0193% | $5.71 | 2 | 0 | <0.0001% |
| Barone Francesca | Chief Scientific Officer | 2738 0.0095% | $5.71 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Northpond Partners LLC | $3.06M | 6.51 | 1.94M | 0% | +$0 | 0.07 | |
| Sands Capital Ventures LLC | $1.28M | 2.73 | 811,737 | 0% | +$0 | 0.31 | |
| The Vanguard Group | $855,246.00 | 1.82 | 541,295 | +27.14% | +$182,562.66 | <0.0001 | |
| Geode Capital Management | $230,256.00 | 0.49 | 145,706 | +4.63% | +$10,197.53 | <0.0001 | |
| Bridgeway Capital Management | $130,500.00 | 0.28 | 82,595 | -37.71% | -$78,999.94 | <0.01 | |
| Renaissance Technologies | $90,000.00 | 0.19 | 56,905 | +204.71% | +$60,463.93 | <0.0001 | |
| BlackRock | $75,177.00 | 0.16 | 47,580 | -3.46% | -$2,693.92 | <0.0001 | |
| Mariner Llc | $52,898.00 | 0.11 | 33,480 | New | +$52,898.00 | <0.0001 | |
| Resources Investment Advisors Inc | $47,057.00 | 0.1 | 29,783 | 0% | +$0 | <0.01 | |
| State Street | $43,608.00 | 0.09 | 27,600 | 0% | +$0 | <0.0001 | |
| Northern Trust | $30,821.00 | 0.07 | 19,507 | -0.56% | -$173.80 | <0.0001 | |
| Two Sigma | $21,186.00 | 0.05 | 13,409 | New | +$21,186.00 | <0.0001 | |
| Tower Research Capital | $5,849.00 | 0.01 | 3,702 | -45.02% | -$4,788.85 | <0.0001 | |
| JPMorgan Chase | $349.00 | <0.01 | 221 | +5.74% | +$18.95 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 69 | +130% | +$0 | <0.0001 | |
| UBS | $16.00 | <0.01 | 10 | -99.92% | -$19,057.60 | <0.0001 | |
| Wells Fargo | $182.00 | <0.01 | 115 | +1.77% | +$3.17 | <0.0001 | |
| Qube Research & Technologies | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 |